NCT06917001

Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)

A Randomized, Double-blind, Placebo-controled, Phase 2a Trial Evaluating the Safety and Initial Efficacy of Resomelagon in Patients With Dengue Infection

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Federal University of Minas Gerais · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are: Is Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.

Conditions

• Dengue Fever

Interventions

Type	Name	Description
DRUG	Resomelagon	Resomelagon 100mg, orally, once daily.
DRUG	Placebo	Placebo
OTHER	Standard Treatment	Hydration and symptomatic therapy as indicated for Dengue fever.

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-06-01
• Completion: 2027-12-01
• First posted: 2025-04-08
• Last updated: 2025-08-28

Locations

2 sites across 1 country: Brazil